London
· Delayed Price · Currency is GBP · Price in CHF Newron Pharmaceuticals Statistics
Total Valuation
Newron Pharmaceuticals has a market cap or net worth of GBP 167.04 million. The enterprise value is 198.27 million.
| Market Cap | 167.04M |
| Enterprise Value | 198.27M |
Important Dates
The next estimated earnings date is Tuesday, April 1, 2025.
| Earnings Date | Apr 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.01% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 18.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.42 |
| EV / Sales | 33.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.48 |
Financial Position
The company has a current ratio of 3.73
| Current Ratio | 3.73 |
| Quick Ratio | 3.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.65 |
| Interest Coverage | -3.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.24% |
| Return on Invested Capital (ROIC) | -42.51% |
| Return on Capital Employed (ROCE) | -76.72% |
| Revenue Per Employee | 268,605 |
| Profits Per Employee | -725,695 |
| Employee Count | 22 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.52% in the last 52 weeks. The beta is 0.94, so Newron Pharmaceuticals's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +19.52% |
| 50-Day Moving Average | 8.19 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 61.48 |
| Average Volume (20 Days) | 1,191 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Newron Pharmaceuticals had revenue of GBP 5.91 million and -15.97 million in losses. Loss per share was -0.88.
| Revenue | 5.91M |
| Gross Profit | 5.91M |
| Operating Income | -12.72M |
| Pretax Income | -15.94M |
| Net Income | -15.97M |
| EBITDA | -12.61M |
| EBIT | -12.72M |
| Loss Per Share | -0.88 |
Balance Sheet
The company has 10.33 million in cash and 41.42 million in debt, giving a net cash position of -31.08 million.
| Cash & Cash Equivalents | 10.33M |
| Total Debt | 41.42M |
| Net Cash | -31.08M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -26.14M |
| Book Value Per Share | -1.37 |
| Working Capital | 12.47M |
Cash Flow
In the last 12 months, operating cash flow was -11.33 million and capital expenditures -8,478, giving a free cash flow of -11.34 million.
| Operating Cash Flow | -11.33M |
| Capital Expenditures | -8,478 |
| Free Cash Flow | -11.34M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -215.29% and -270.17%.
| Gross Margin | 100.00% |
| Operating Margin | -215.29% |
| Pretax Margin | -269.80% |
| Profit Margin | -270.17% |
| EBITDA Margin | -213.41% |
| EBIT Margin | -215.29% |
| FCF Margin | n/a |
Dividends & Yields
Newron Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.01% |
| Shareholder Yield | -2.01% |
| Earnings Yield | -9.56% |
| FCF Yield | -6.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Newron Pharmaceuticals has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | n/a |